Cargando…

Treatment outcome in children with central nervous system-positive Burkitt lymphoma using only intrathecal and systemic chemotherapy combined with rituximab

BACKGROUND: With current chemotherapy treatment, >90% of survival has been obtained for Burkitt lymphoma (BL). In this study, the demographic characteristics and treatment outcomes are presented for 78 children in China with central nervous system-positive (CNS+) BL. METHODS: This retrospective s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Shuang, Jin, Lin, Yang, Jing, Duan, Yan-Long, Zhang, Meng, Zhou, Chun-Ju, Zhang, Yong-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183724/ https://www.ncbi.nlm.nih.gov/pubmed/33734131 http://dx.doi.org/10.1097/CM9.0000000000001386

Ejemplares similares

Be mindful of the central nervous system in Burkitt lymphoma
por: Roschewski, Mark
Publicado: (2021)

The Role of Rituximab in Primary Central Nervous System Lymphoma
por: Bromberg, Jacoline E. C., et al.
Publicado: (2020)

The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma
por: Van Dijck, Ruben, et al.
Publicado: (2021)

Primary Central Nervous System Burkitt Lymphoma in HIV Positive Pediatric Patient: A Rare Case Report
por: Patel, Priyanka A., et al.
Publicado: (2019)

Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review
por: Eyre, Toby A., et al.
Publicado: (2020)

Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma
por: Sun, Xuefei, et al.
Publicado: (2017)

Burkitt Lymphoma with Initial Clinical Presentation due to Infiltration of the Central Nervous System and Eye Orbits
por: Camilo, Gustavo Bittencourt, et al.
Publicado: (2014)

A Case of the Cauda Equina Syndrome Associated With the Intrathecal Chemotherapy in a Patient With Primary Central Nervous System Lymphoma
por: Park, Seunglee, et al.
Publicado: (2013)

ML-14 LOW INVASIVE APPROACH FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA TREATMENT INVOLVING RITUXIMAB–METHOTREXATE + PROCARBAZINE + VINCRISTINE AND TRIPLE INTRATHECAL INJECTION
por: Ogawa, Takahiro, et al.
Publicado: (2019)

ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
por: Takezaki, Tatsuya, et al.
Publicado: (2020)

Combination Therapy with Rituximab and Temozolomide for Recurrent and Refractory Primary Central Nervous System Lymphoma
por: Murakami, Mineko, et al.
Publicado: (2011)

Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study
por: Zayac, Adam S., et al.
Publicado: (2021)

Midostaurin potentiates rituximab antitumor activity in Burkitt’s lymphoma by inducing apoptosis
por: Ge, Xiaowen, et al.
Publicado: (2018)

Interstitial pneumonitis during rituximab-containing chemotherapy for primary central nervous system lymphomas: a case report and review of literature
por: Wu, Yuchen, et al.
Publicado: (2018)

Comparison of chemotherapy regimens plus rituximab in adult Burkitt lymphoma: A single-arm meta-analysis
por: Lu, Xiaoxuan, et al.
Publicado: (2022)

Primary Central Nervous System Burkitt Lymphoma With Non-Immunoglobulin Heavy Chain Translocation in Right Ventricle: Case Report
por: Jiang, Ming, et al.
Publicado: (2011)

Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement
por: Trysberg, Estelle, et al.
Publicado: (2004)

Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma
por: Zhao, Defeng, et al.
Publicado: (2014)

Efficacy and Safety of Rituximab in Central Nervous System Demyelinating Disorders
por: Patil, Varsha A., et al.
Publicado: (2021)

Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma: effectiveness of rituximab-containing chemotherapy including central nervous system prophylaxis
por: Ichikawa, Satoshi, et al.
Publicado: (2013)

Primary Central Nervous System Lymphoma
por: Dong, Yan-Hong, et al.
Publicado: (2016)

Research on the Damage of the Central Nervous System Lymphoma to the Nervous System
por: Hernandez, Jairo, et al.
Publicado: (2023)

Fate of nanoparticles in the central nervous system after intrathecal injection in healthy mice
por: Householder, K. T., et al.
Publicado: (2019)

Intrathecal tigecycline is a safe and effective treatment for central nervous system infections
por: Mastroianni, Antonio, et al.
Publicado: (2023)

Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience
por: Suleman, Adam, et al.
Publicado: (2022)

Survival improvement with combined radio-chemotherapy in the primary central nervous system lymphomas.
por: Wu, H. G., et al.
Publicado: (1999)

Primary central nervous system lymphoma
por: Gloghini, Annunziata, et al.
Publicado: (2015)

Primary central nervous system lymphoma
por: Löw, Sarah, et al.
Publicado: (2018)

Rare central nervous system lymphomas
por: Kaji, Furqaan Ahmed, et al.
Publicado: (2022)

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis
por: Hong, Junshik, et al.
Publicado: (2015)

Intraoral Burkitt's lymphoma in an HIV positive patient
por: Ajila, Vidya, et al.
Publicado: (2012)

Systemic vs. intrathecal central nervous system prophylaxis in primary adrenal/renal diffuse large b-cell LYMPHOMA: A multi-institution retrospective analysis and systematic review
por: Xie, John, et al.
Publicado: (2021)

Use of rituximab, temozolomide, and radiation in recurrent and refractory primary central nervous system lymphoma in the Philippines: a retrospective analysis
por: Batara, Julette Marie F, et al.
Publicado: (2022)

Late recurrence of Burkitt’s lymphoma in the jaw: numb chin syndrome as the only symptom
por: Benites, Bernar Monteiro, et al.
Publicado: (2020)

Primary Central Nervous System Lymphoma With Systemic Recurrence
por: Pandravada, Sasirekha, et al.
Publicado: (2021)

HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era
por: Rodrigo, J. A., et al.
Publicado: (2012)

A Search for the Burkitt Lymphoma in Tropical Central America
por: Rowe, N. H., et al.
Publicado: (1964)

Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas
por: Kim, Young-Joo, et al.
Publicado: (2015)

Characteristics of Central Nervous System (CNS) Involvement in Children With Non-Hodgkin’s Lymphoma (NHL) and the Diagnostic Value of CSF Flow Cytometry in CNS Positive Disease
por: Huang, Shuang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3pu35bpgqi9udtlelid25em5gc